Table 2.
The pathways involved in differentially expressed genes compared with different time points following AMI
| Pathways | Q-value (Q < 0.05) | |
|---|---|---|
| admission versus control group | Natural killer cell mediated cytotoxicity | 3.142005e−09 |
| Graft-versus-host disease | 5.779472e−07 | |
| Antigen processing and presentation | 2.997803e−03 | |
| Cytosolic DNA-sensing pathway | 2.302012e−02 | |
| discharge versus control group | Natural killer cell mediated cytotoxicity | 8.154634e−10 |
| Graft-versus-host disease | 1.164728e−08 | |
| Antigen processing and presentation | 1.657503e−04 | |
| Allograft rejection | 2.438676e−02 | |
| admission versus 6 months | Oxidative phosphorylation | 3.841450e−15 |
| Huntington’s disease | 1.570003e−12 | |
| Parkinson’s disease | 2.462576e−12 | |
| Alzheimer’s disease | 1.076534e−11 | |
| discharge versus 6 months | Parkinson’s disease | 4.627948e−16 |
| Oxidative phosphorylation | 4.627948e−16 | |
| Alzheimer’s disease | 9.071314e−15 | |
| Huntington’s disease | 8.428429e−14 |